[Assessment of the therapeutic possibilities of systemic radiotherapy as a component of combined treatment for advanced ovarian carcinoma].

The new technology of combined treatment for patients with ovarian carcinoma of III-IV stages and its relapse is presented. The essentially new component is systemic radiotherapy in nontumoricidal doses. It is used with both traditional surgical and chemotherapeutic components.

[The mechanism of the antitumor effect of total/subtotal radiotherapy with non-tumoricidal doses of radiation].

The myelodepression at therapy for solid malignancies is considered as a mediating element of common antineoplastic activity on the basis of ability of stem cells of hemapoietic system to participate in regeneration of the various tissues of the body, including tumor. The equivalence of the therapeutic benefit mediated by both mild myelodepression due to total/subtotal radiation exposure and conventional chemotherapy with cytotoxic drugs is argued.

[Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].

Blood CA125 carbohydrate antigen levels were measured in 131 patients with malignant, benign, and borderline ovarian diseases. Parallel measurements of carcinoembryonic antigen (CEA) were carried out in 101 of them. The diagnosis with CA125 measurements was found highly sensitive (96%), specific (77%), and accurate (73%).

[Alterations of c-myc and c-Ha-ras-1 oncogenes in human ovarian cancer].

Fourteen cases of the ovarian carcinoma (OC) were studied for alterations of c-myc and c-Ha-ras-1 oncogens. Amplification of c-myc was found in four aggressive and widespread OC. An increased frequency of one of the four common alleles of c-Ha-ras-1-allele A4-was determined in OC patients.